Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529613) titled 'Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma' on April 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Center Hospital East
Condition:
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Intervention:
Drug: T-DXd
Drug: Nivolumab
Drug: Capecitabine
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: December 20, 2023
Target ...